Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**ETS domain-containing transcription factor ERF** is a member of the ETS family of transcription factors that acts as a strong transcriptional repressor[1][2]. It binds ETS-binding sites (EBS) in gene promoters and suppresses the transcriptional activity of ETS gene activators. ERF negatively regulates the oncogenic activity of other ETS factors and can suppress certain tumorigenic pathways. Its activity is modulated by phosphorylation, especially via the MAPK/ERK signaling pathway, linking it to cellular responses to mitogenic stimulation and cell cycle transitions. Alteration of ERF function or regulation contributes to tumorigenesis and dysregulation of cell proliferation[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ETS domain-containing transcription factor ERF (ERF).